Targeting SOX-2 driven cancer stem cells has demonstrated the clinical promise of iadademstat as an anti-ti-SOX2 epigenetic breast cancer treatment, especially in the SOX2-rich luminal-B HER2+ type. This evidence concerns the gene ERBB2 and cancer.